Fatostatin 125B11|cas:125256-00-0|西域试剂

Fatostatin 125B11,99.96%

产品编号：Bellancom-14452| CAS NO：125256-00-0| 分子式：C₁₈H₁₈N₂S| 分子量：294.41

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14452	￥660.00	杭州北京（现货）
Bellancom-14452	￥1000.00	杭州北京（现货）
Bellancom-14452	￥2200.00	杭州北京（现货）
Bellancom-14452	￥3800.00	杭州北京（现货）
Bellancom-14452	￥6900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Fatostatin 125B11

产品介绍

Fatostatin (125B11) 是 SREBP 活化的特异性抑制剂，可抑制 SREBP-1 和 SREBP-2 的活化。Fatostatin 与 SCAP (SREBP裂解激活蛋白) 结合，抑制 SREBPs 的 ER-Golgi 易位。Fatostatin 降低了细胞中成脂基因的转录。Fatostatin 具有抗肿瘤作用，能降低 ob/ob 小鼠的高血糖。

生物活性

Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.

体外研究

Fatostatin (125B11) (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC₅₀=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin inhibits insulin-induced adipogenesis of 3T3-L1 cells.
Fatostatin directly binds SCAP and blocks its ER-to-Golgi transport with IC₅₀ of 2.5 and 10 μM in mammalian cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	DU-145 cells
Concentration:	0.1, 1 μM
Incubation Time:	3 days
Result:	Impaired the IGF1-induced growth at an IC₅₀ of 0.1 μM.

体内研究
(In Vivo)

Fatostatin (125B11) (30 mg/kg; 150 μL; i.p. injection; daily for 28 days) reduces adiposity, ameliorated fatty liver by reducing triglyceride (TG) storage, and lowered hyperglycemia in ob/ob mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)
Dosage:	30 mg/kg; 150 μL
Administration:	i.p. injection; daily for 28 days
Result:	Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake.

体内研究

Fatostatin (125B11) (30 mg/kg; 150 μL; i.p. injection; daily for 28 days) reduces adiposity, ameliorated fatty liver by reducing triglyceride (TG) storage, and lowered hyperglycemia in ob/ob mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)
Dosage:	30 mg/kg; 150 μL
Administration:	i.p. injection; daily for 28 days
Result:	Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake.

体内研究

Fatostatin (125B11) (30 mg/kg; 150 μL; i.p. injection; daily for 28 days) reduces adiposity, ameliorated fatty liver by reducing triglyceride (TG) storage, and lowered hyperglycemia in ob/ob mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)
Dosage:	30 mg/kg; 150 μL
Administration:	i.p. injection; daily for 28 days
Result:	Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 27 mg/mL (91.71 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3966 mL	16.9831 mL	33.9662 mL
5 mM	0.6793 mL	3.3966 mL	6.7932 mL
10 mM	0.3397 mL	1.6983 mL	3.3966 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.49 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.49 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (8.49 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (8.49 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: 2.5 mg/mL (8.49 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (8.49 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。